BriaCell Therapeutics Corp. announces the completion of patient enrollment in its Phase 2 clinical study and reports clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients. Phase 2 Combination Study of Bria-IMT?

with Immune Check Point Inhibitor The Phase 2 study is fully enrolled. To date, 46 heavily pre-treated (average number of prior treatments = 5) advanced metastatic breast cancer patients have been enrolled in the study evaluating BriaCell?s lead clinical candidate, Bria-IMT?, and immune check point inhibitor combination regimen {11 patients with Merck & Co. Inc.?s KEYTRUDA® (pembrolizumab), and 36 patients with Incyte?s ZYNYZ?

(retifanlimab-dlwr) with one patient cross over from the KEYTRUDA® study to the ZYNYZ? study}. 29 patients have received treatment since 2022.

Tolerability: The tolerability of the treatment regimen remains excellent with no dose limiting toxicities. Survival Update: 21 out of 29 patients that have received treatment since 2022 remain alive suggesting tolerability and survival efficacy. The data is not yet mature as patients continue to remain on the study.

Median overall survival rate in all patients has been recorded at 13.5 months using Kaplan-Meier curve method which measures the probability of patients? survival in time. The overall survival in advanced breast cancer patients (third line or later) is very limited, 6.7-9.8 months in publications that evaluated similar patients.

The survival findings support BriaCell?s hypothesis of additive and/or synergistic effects of immune check point inhibitors with Bria-IMT? and support using this combination regimen for upcoming pivotal study in advanced breast cancer.